Apogee Therapeutics (APGE) Net Cash Flow (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Net Cash Flow of $320.2 million for Q1 2026, up 1018.24% year-over-year from $28.6 million in Q1 2025, and up 1257.72% quarter-over-quarter from $23.6 million in Q4 2025.
Apogee Therapeutics (APGE) Net Cash Flow (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Net Cash Flow for 5 consecutive years, with $320.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1018.24% year-over-year to $320.2 million; the TTM figure through Mar 2026 stood at $344.5 million (up 191.01% YoY), while the FY2025 annual figure was -$10.6 million, down 145.09% from the prior year.
- Net Cash Flow climbed to $320.2 million in Q1 2026 per APGE's latest filing, from $23.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $367.1 million in Q1 2024 and bottomed at -$188.5 million in Q3 2024.
- Historically, Net Cash Flow has averaged $46.0 million across 5 years, with a median of $4.8 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 6036.13% — and 2024, when it sank 1122.77%.
- Apogee Therapeutics' Net Cash Flow stood at $149.3 million in 2022, then plunged by 146.65% to -$69.7 million in 2023, then surged by 133.03% to $23.0 million in 2024, then gained by 2.5% to $23.6 million in 2025, then soared by 1257.72% to $320.2 million in 2026.
- Business Quant data shows APGE's Net Cash Flow at $320.2 million in Q1 2026, $23.6 million in Q4 2025, and -$16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | -346.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -346.25 Mn |
| Jun 30, 2026 | -346.25 Mn |
| Mar 31, 2026 | 320.22 Mn |
| Mar 31, 2026 | 320.22 Mn |
| Dec 31, 2025 | 23.59 Mn |
| Dec 31, 2025 | 23.59 Mn |
| Sep 30, 2025 | -16.58 Mn |
| Sep 30, 2025 | -16.58 Mn |
| Jun 30, 2025 | 17.28 Mn |
| Jun 30, 2025 | 17.28 Mn |
| Mar 31, 2025 | -34.87 Mn |
| Mar 31, 2025 | -34.87 Mn |
| Dec 31, 2024 | 23.01 Mn |
| Dec 31, 2024 | 23.01 Mn |
| Sep 30, 2024 | -188.52 Mn |
| Sep 30, 2024 | -188.52 Mn |
| Jun 30, 2024 | -178.16 Mn |
| Jun 30, 2024 | -178.16 Mn |
| Mar 31, 2024 | 367.14 Mn |
| Mar 31, 2024 | 367.14 Mn |